Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Survival Impact of Biomarker Identified in Phase III Trial of Melanoma Drug

  • Genta presented the results of a collaborative study by Genta and the Melanoma Group of the European Organization for the Research and Treatment of Cancer. The results confirmed the strong relationship between patient survival and a biomarker that was prospectively studied in the randomized Phase III trial of Genasense® (oblimersen sodium) injection in patients with advanced melanoma.

    Genta says the Genasense data derives from the largest randomized controlled trial ever conducted in patients with advanced melanoma. In this trial, 771 patients were randomly assigned to receive chemotherapy with dacarbazine alone or in combination with Genasense. The results of this trial showed that multiple outcomes, including overall survival, progression-free survival, overall response, and durable response, were strongly associated with blood levels of an enzyme known as LDH, a biomarker that was a prospectively defined stratification factor.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »